ArticleHuman genomics2026
Integrating single-cell multi-omics and machine learning to reveal triaptosis heterogeneity in clear cell renal cell carcinoma.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Triaptosis, an emerging form of cell death, remains poorly characterized in terms of its heterogeneity within clear cell renal cell carcinoma (ccRCC). Utilizing single-cell transcriptomics, we delineate a landscape of triaptosis heterogeneity and identify monocytes and macrophages as exhibiting the highest triaptosis activity, which further increases upon terminal differentiation. These high-activity cells also demonstrate enhanced pro-angiogenic signaling toward endothelial cells. Within epithelial cells, subpopulations with the strongest triaptosis activity are located at the late differentiation stage and are closely associated with ccRCC traits. Spatial transcriptomic analysis reveals a decline in triaptosis activity with increasing distance from the tumor epithelial core. The epithelial cluster with the highest triaptosis activity showed reduced metabolic activity. In bulk transcriptome analysis, patients with high epithelial triaptosis activity infiltration exhibited improved prognosis, broader immune activation, and similarly suppressed metabolism. We subsequently developed a robust 4-gene prognostic signature based on module genes derived from high-triaptosis epithelial subpopulations. This model showed strong performance in prognostic stratification, immunotherapy guidance, and chemotherapy response prediction. Finally, we identified SLC25A37 as a core oncogenic gene within the signature and proposed Yohimbic acid among several potential molecularly targeted therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.